Brought to you by 
Genzyme, Cell Genesys merger terminated
15 Feb 2000
Executive Summary
Genzyme General is buying Cell Genesys (gene therapy) for $350mm worth of Genzyme common stock. The acquisition values each Cell Genesys share at $10, a (pr)26% premium to its 10-day trailing average, and should close in the first quarter of next year. The agreement includes a collar: the exchange ratio will not be greater than 0.317 or less than 0.181 Genzyme share.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme, Cell Genesys merger terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice